Artiklar

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).¹

Autoimmune type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.^1–3 You can identify such patients at risk of developing autoimmune T1D before clinical symptoms are noticed by you or your patient.³

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Fabry disease is an X-linked lysosomal storage disease due to a defect in the gene encoding the lysosomal enzyme alpha-galactosidase A (α-Gal A), causing progressive cellular accumulation of the substrate globotriaosylceramide (GL-3) and globo-triaosylsphingosine (lyso-GL-3).

Think Fabry, think timely testing first.

Think Fabry, think regular profile-based assessments.

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.¹